The therapeutic community is buzzing with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 receptor that’s exhibiting significant efficacy in clinical trials for addressing obesity. Unlike some current weight loss approaches, retatrutide appears to provide a more substantial decrease in body mass and improve metabolic function, pa